Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00334282 · OUTCOME

Plasma Pazopanib Concentrations Before Dosing and at 2, 4, and 8 Hours After Dosing on Day 1 and Week 3

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma · Source last updated 2016-02-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
nanograms per milliliter
Interval / dispersion
Full Range
Time frame
Day 1 and Week 3

What was measured

The concentration of pazopanib in the plasma was measured.

Analysis population: Subgroup of enrolled participants who agreed to have blood samples collected for analysis of pazopanib in plasma. Data were missing or not collected at Week 3 for 8 participants for whom data were available on Day 1. No samples were collected at Week 3 from 2 participants.

Groups in this outcome

Pazopanib 800 mg

Pazopanib 800 mg (tablets) administered once daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pazopanib 800 mg57

Reported measurements

Day 1, before dosing, n=57
Values in nanograms per milliliter · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg0Not reported0846Not reported
Week 3, before dosing, n=48
Values in nanograms per milliliter · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg31851Not reported263461720Not reported
Day 1, 2 hours after dosing, n=57
Values in nanograms per milliliter · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg17270Not reported0107454Not reported
Week 3, 2 hours after dosing, n=49
Values in nanograms per milliliter · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg42205Not reported428279977Not reported
Day 1, 4 hours after dosing, n=57
Values in nanograms per milliliter · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg24360Not reported237174606Not reported
Week 3, 4 hours after dosing, n=49
Values in nanograms per milliliter · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg42637Not reported3532107972Not reported
Day 1, 8 hours after dosing, n=57
Values in nanograms per milliliter · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg19925Not reported327360974Not reported
Week 3, 8 hours after dosing, n=48
Values in nanograms per milliliter · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Pazopanib 800 mg40177.5Not reported376096548Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        846
        value
        0
    title
    Day 1, before dosing, n=57
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2634
        upper Limit
        61720
        value
        31851
    title
    Week 3, before dosing, n=48
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        107454
        value
        17270
    title
    Day 1, 2 hours after dosing, n=57
  4. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4282
        upper Limit
        79977
        value
        42205
    title
    Week 3, 2 hours after dosing, n=49
  5. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2371
        upper Limit
        74606
        value
        24360
    title
    Day 1, 4 hours after dosing, n=57
  6. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3532
        upper Limit
        107972
        value
        42637
    title
    Week 3, 4 hours after dosing, n=49
  7. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3273
        upper Limit
        60974
        value
        19925
    title
    Day 1, 8 hours after dosing, n=57
  8. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3760
        upper Limit
        96548
        value
        40177.5
    title
    Week 3, 8 hours after dosing, n=48
denoms
  1. counts
    1. group Id
      OG000
      value
      57
    units
    Participants
description
The concentration of pazopanib in the plasma was measured.
dispersion Type
Full Range
groups
  1. description
    Pazopanib 800 mg (tablets) administered once daily
    id
    OG000
    title
    Pazopanib 800 mg
param Type
MEDIAN
population Description
Subgroup of enrolled participants who agreed to have blood samples collected for analysis of pazopanib in plasma. Data were missing or not collected at Week 3 for 8 participants for whom data were available on Day 1. No samples were collected at Week 3 from 2 participants.
reporting Status
POSTED
time Frame
Day 1 and Week 3
title
Plasma Pazopanib Concentrations Before Dosing and at 2, 4, and 8 Hours After Dosing on Day 1 and Week 3
type
SECONDARY
unit Of Measure
nanograms per milliliter

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice